-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from 2021 to 2023.
- Inhibikase Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 8.88M shares, a 66.3% increase year-over-year.
- Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 5.33M shares, a 26.3% increase from 2022.
- Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 4.22M shares, a 76.8% decline from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)